- Details
- (Length of Discussion: 12 min) Alicia Morgans and Josh Meeks highlight ongoing trials in non-muscle invasive bladder cancer. Reviews of SWOG 1602 and 1605, highlight the great work being done in the search for treatment options for patients with this disease, the ultimate hope for patients is to retain their bladder and potentially be cancer-free. Biographies: Joshua J Meeks, MD, Ph.D., is an Assi...
|
- Details
- Cora Sternberg highlights from a number of key treatments in GU Oncology in a discussion with Alicia Morgans. Results from the only Phase 3 health-related quality-of-life (HRQoL) analyses in urothelial carcinoma from the KEYNOTE-045 study delivers results for patients who received 2 nd line therapy. A relevant discussion follows on a Phase 2 trial investigating 3 different dosing regimens of radiu...
|
- Details
- (Length of Discussion: 3 min) Diane Newman and Eric Rovner discuss a newly published book on urologic devices and catheters. This book is written for the urology and gynecology community and mindfully designed to be a great resource for patients as well. The book houses a breadth of topics from urologic devices, skin care, catheter options, and procedures. Biographies: Diane K. Newman, DNP Eric S....
|
- Details
- (Length of Presentation: 10 min) Alicia Morgans, MD and Bishoy Faltas, MD have an energetic conversation about the tremendous progress they have seen in the recent years in bladder cancer. Dr. Faltas takes us through some of the current research with IO therapy, specifically checkpoint inhibition; where they are currently used and where the clinical data may expand the use of these agents. He revi...
|
- Details
- (Length of Discussion: 30 min) Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018. This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx. He discusses the clinical applica...
|
- Details
- (Length of Discussion: 16 min) Petros Grivas and Alicia Morgans discuss the late-breaking FDA Alert announcing the label changes for Pembrolizumab and Atezolizumab as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1. Biographies: Petros Grivas MD, Ph.D. a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate c...
|
- Details
- (Length of conversation: 14 minutes) Alicia Morgans and Arjun Balar converse on the long-term efficacy data of atezolizumab in the 1st line setting as well as the 2nd line setting from the single-arm phase 2 trial. Discussion evolves to the recent safety alerts by the FDA highlighting the two studies, Keynote 361 and IMvigor 130. They question the applicability to clinical practice and the challen...
|
- Details
- Medical oncologist, bladder cancer survivor, and author of Journey from Oncologist to Cancer Survivor and Patient Advocate in the Era of Precision Medicine, Burt Needles who was diagnosed with a rare form of bladder cancer, plasmacytoid variant in 2013, talks with Alicia Morgans about his unique perspective as a medical oncologist and clinician to a cancer survivor and patient advocate. Biographie...
|
- Details
- (Length of Discussion: 11 min) Ashish Kamat, MD, MPH and Alicia Morgans, MD discuss non-muscle invasive bladder cancer, where the field stands particularly for BCG refractory patients and the definition of the BCG unresponsive patient. Ashish overviews the efforts of the SUO-CTC Bladder Committee and important updates and trials in this disease state . Biographies: Ashish M. Kamat, MD Alicia Morga...
|
- Details
- Stephen Williams and Ashish Kamat discuss the paper, Impact of Psychiatric Illness on Decreased Survival in Elderly Patients with Bladder Cancer in the United States, a study which addresses problems that bladder cancer patients face and the difficulties they experience coping after major interventions for bladder cancer therapy. The conversation also includes recommendations on how to educate and...
|
